Partner Content Partner Content Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018 Pharma Giants Unite to Improve Rare Disease Treatment
Partner Content Partner Content Patient Organisations role in Orphan Drugs clinical developm... Orphan Drugs and Rare Diseases Conference - London
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
